Targeting the IL-6/STAT3 Signalling Cascade to Reverse Tamoxifen Resistance in Estrogen Receptor Positive Breast Cancer
Breast cancer is the most common female cancer. About 70% of breast cancer patients are estrogen receptor α (ERα) positive (ER+) with tamoxifen being the most commonly used anti-endocrine therapy. However, up to 50% of patients who receive tamoxifen suffer recurrence. We previously identified BQ3236...
Main Authors: | Ho Tsoi, Ellen P. S. Man, Ka Man Chau, Ui-Soon Khoo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/7/1511 |
Similar Items
-
The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)
by: E. L. Nasonov, et al.
Published: (2022-11-01) -
Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy
by: Yoshihito Shima
Published: (2021-05-01) -
INNOVATIVE TREATMENTS FOR TAKAYASU’S ARTERITIS: A FOCUS ON INTERLEUKIN-6 INHIBITORS. THE AUTHORS’ EXPERIENCE WITH TOCILIZUMAB AND A REVIEW OF LITERATURE
by: T. V. Beketova, et al.
Published: (2017-10-01) -
INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
by: E. L. Nasonov, et al.
Published: (2018-01-01) -
Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer
by: Ho Tsoi, et al.
Published: (2022-01-01)